US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

8.87

+0.10001.14%

Post-market: 9.060.1900+2.14%17:17 EDT

Volume:756.94K

Turnover:6.73M

Market Cap:536.10M

PE:-2.43

High:9.18

Open:8.57

Low:8.50

Close:8.77

52wk High:13.67

52wk Low:1.78

Shares:60.44M

Float Shares:33.30M

Volume Ratio:1.02

T/O Rate:2.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.6445

EPS(LYR):-3.6445

ROE:-64.67%

ROA:-35.47%

PB:2.31

PE(LYR):-2.43

Loading ...

Overview Company News Filings

Press Release: Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia

BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow

Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM

Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder

Kyverna Therapeutics Shares Jump 39% After Co's Cell Therapy Meets Main Goal of Mid-Stage Study

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNow

Kyverna Exec Says in Kysa-8 Trial, Median Age of 26 Patients Was 56 Years - Conf Call

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Rocket Lab, Applied Materials

Kyverna Says Trial of Treatment for Stiff Person Syndrome Showed 'Significant' Benefit in Primary, Secondary Endpoints

MT Newswires Live

Kyverna Therapeutics Shares Surge 24% Premarket After Positive Trial Data

THOMSON REUTERS

Kyverna's cell therapy meets main goal of mid-stage study

Kyverna Therapeutics Inc - Miv-Cel Well-Tolerated With No High-Grade Crs or Icans

THOMSON REUTERS

Kyverna Therapeutics Inc - Miv-Cel Achieves Significant Clinical Benefit After One Dose

THOMSON REUTERS

Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial of Miv-Cel (Kyv-101) in Stiff Person Syndrome

THOMSON REUTERS

Kyverna Therapeutics Inc - to Submit Bla to FDA for SPS in 1H 2026

THOMSON REUTERS

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics Shares Gain Ahead of Mid-Stage Trial Results

Kyverna Therapeutics to Report Topline Phase 2 Results for KYV-101 in Stiff Person Syndrome

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KYTX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.87,"timestamp":1775160000000,"preClose":8.77,"halted":0,"volume":756940,"hourTrading":{"tag":"盘后","latestPrice":9.06,"preClose":8.87,"latestTime":"17:17 EDT","volume":5356,"amount":47476.564148000005,"timestamp":1775164638628,"change":0.19,"changeRate":0.021421,"amplitude":0.038331},"delay":0,"changeRate":0.011402508551881374,"floatShares":33297000,"shares":60439900,"eps":-3.644532,"marketStatus":"Post-Mkt","change":0.1,"latestTime":"04-02 17:51:45 EDT","open":8.57,"high":9.18,"low":8.5023,"amount":6733889.6280000005,"amplitude":0.077275,"askPrice":9.71,"askSize":100,"bidPrice":8.48,"bidSize":240,"shortable":3,"etf":0,"ttmEps":-3.644532,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775174400000},"marketStatusCode":4,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.77,"preHourTrading":{"tag":"盘前","latestPrice":8.8587,"preClose":8.77,"latestTime":"09:11 EDT","volume":2780,"amount":23513.7682,"timestamp":1775135479779,"change":0.0887,"changeRate":0.010114,"amplitude":0.068655},"postHourTrading":{"tag":"盘后","latestPrice":9.06,"preClose":8.87,"latestTime":"17:17 EDT","volume":5356,"amount":47476.564148000005,"timestamp":1775164638628,"change":0.19,"changeRate":0.021421,"amplitude":0.038331},"volumeRatio":1.022019,"impliedVol":1.0653,"impliedVolPercentile":0.1992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":33297000,"roa":"-35.47%","roe":"-64.67%","lyrEps":-3.644532,"volumeRatio":1.022019,"shares":60439900,"dividePrice":0,"high":9.18,"amplitude":0.077275,"preClose":8.77,"low":8.5023,"week52Low":1.78,"pbRate":"2.31","psRate":"1901.07","week52High":13.67,"institutionHeld":0,"latestPrice":8.87,"committee":0.411765,"eps":-3.644532,"divideRate":0,"volume":756940,"delay":0,"ttmEps":-3.644532,"open":8.57,"prevYearClose":9.4,"prevWeekClose":7.8,"prevMonthClose":8.63,"prevQuarterClose":8.63,"fiveDayClose":8.03,"twentyDayClose":8.39,"sixtyDayClose":7.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-26","symbol":"KYTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.8},{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97},{"market":"US","date":"2025-05-13","symbol":"KYTX","fiscalQuarterEnding":"2025/03","expectedEps":-1.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755748800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-04-01","current":-2.406345,"percent":0.3054,"low":-26.836094,"twenty":-4.643636,"median":-2.218481,"eighty":-1.029019,"high":-0.615209,"avg":-4.512168,"sd":6.165707,"marketCap":521728281},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974},{"date":"2026-02-27","current":-2.881457,"twenty":-4.928528,"median":-2.043785,"eighty":-1.01438,"marketCap":463891564},{"date":"2026-03-06","current":-2.977269,"twenty":-4.827435,"median":-2.086542,"eighty":-1.020777,"marketCap":479316530},{"date":"2026-03-13","current":-3.112116,"twenty":-4.780255,"median":-2.118493,"eighty":-1.024754,"marketCap":501025741},{"date":"2026-03-20","current":-3.030498,"twenty":-4.769593,"median":-2.129165,"eighty":-1.025937,"marketCap":487885955},{"date":"2026-03-27","current":-3.012142,"twenty":-4.692966,"median":-2.151832,"eighty":-1.027873,"marketCap":484930840},{"date":"2026-04-01","current":-3.234381,"twenty":-4.643636,"median":-2.218481,"eighty":-1.029019,"marketCap":521728281}],"updateTime":1775125023852},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591621210","title":"Press Release: Kyverna Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621210?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:01","pubTimestamp":1765832460,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Dec. 15, 2025  -- Kyverna Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the proposed offering will be sold by Kyverna. J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827948.USD","LU0106831901.USD","LU1244550494.USD","LU2023251221.USD","LU1363072403.SGD","LU1791710582.SGD","LU0912757837.SGD","LU0528227936.USD","KYTX","LU0158827781.USD","LU0320765646.SGD","BK4581","LU2111349929.HKD","IE00BKVL7J92.USD","BK4504","LU2271345857.HKD","LU2089284900.SGD","LU0795875169.SGD","IE00BZ1G4Q59.USD","BK4516","LU1732799900.SGD","LU1791710400.SGD","LU2028103732.USD","LU0267386448.USD","LU2357305700.SGD","BK4534","LU1244550577.SGD","LU0098860793.USD","BK4585","LU0106261372.USD","LU2133065610.SGD","LU1548497426.USD","LU0225283273.USD","LU0971096721.USD","LU0314104364.USD","LU1074936037.SGD","LU0882574139.USD","LU1162221912.USD","LU0234570918.USD","LU2347655156.SGD","LU1989772923.USD","LU1244550221.USD","BK4127","BK4588","BK4139","LU0006306889.USD","LU1720051017.SGD","LU1720051108.HKD","LU0557290698.USD","LU0795875086.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591134626","title":"BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2591134626","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591134626?lang=en_us&edition=fundamental","pubTime":"2025-12-16 02:44","pubTimestamp":1765824246,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, NvidiaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL10S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDA","AMAT","LNG","NVDU","CPB","ENTG","TXN","BMY","CNX","CVX","NEM","SNVD.UK","NCLH","JBL","VNDA","FAST","FCX","MOS","XOM","LAZR","IMNM","ALB","LRCX","NVDX","CRBG","NVIW.SI","DG","LYB","TPL","APD","ZTS","HL","SCCO","SPOT","CDE","NVDS.UK","3NVD.UK","INGM","FMC","MIST","NOW","KLAC","APA","KYTX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2591628816","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628816","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628816?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:53","pubTimestamp":1765814010,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, ZillowEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072463663.USD","AMAT","LNG","LU0708995401.HKD","LU0889565833.HKD","TSYW.SI","LU0353189763.USD","LU0053666078.USD","LU0648000940.SGD","CNX","LU1989773731.SGD","NEM","LU1861214812.USD","LU1720051108.HKD","JBL","LU1992135399.USD","FAST","FCX","NCLH","VNDA","LU1223083913.SGD","IMNM","ALB","LRCX","LU1923622614.USD","IE0034235303.USD","CRBG","DG","APD","LU0630314457.HKD","LU1823568750.SGD","LU0654597011.USD","ZTS","HL","SCCO","CDE","INGM","FMC","LU0048573561.USD","LU2357125470.USD","MIST","NOW","KLAC","LYB","KYTX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2591628531","title":"Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628531","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628531?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:45","pubTimestamp":1765813500,"startTime":"0","endTime":"0","summary":"U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Monday.Shares of Kyverna Therapeutics Inc  rose sharply during Monday's session after the company announced topline data from KYSA-8.The clinical-stage biopharmaceutical company shared topline data from the KYSA-8 Phase 2 trial of mivocabtagene autoleucel  in stiff person syndrome .Miv-cel is a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation.Kyverna Therapeutics shares jumped 31% to $11.49 on Monday.Here are some other big stocks recording gains in today’s session.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49395988/kyverna-therapeutics-immunome-almonty-industries-and-other-big-stocks-moving-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49395988/kyverna-therapeutics-immunome-almonty-industries-and-other-big-stocks-moving-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4168","ALM","BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591647573","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:54 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647573","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647573?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:54","pubTimestamp":1765810475,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:54 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nAQN2LDO3G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591902647","title":"Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2591902647","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591902647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:48","pubTimestamp":1765810080,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  stock rose Monday, with a session volume of 6.80 million compared to the average volume of 696.68 thousand as per data from Benzinga Pro.The clinical-stage biopharmaceutical company shared topline data from the KYSA-8 Phase 2 trial of mivocabtagene autoleucel  in stiff person syndrome .Miv-cel is a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation.Also Read: Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026. Stiff Person Syndrome is a rare autoimmune neurological disorder causing progressive muscle stiffness, rigidity, and painful spasms, primarily in the torso and limbs, triggered by stimuli like noise or touch, leading to falls and disability as it worsens over time.It results from the immune system mistakenly attacking nerve cells controlling muscle movement.The single-arm registrational Phase 2 trial dosed 26 patients who had an inadequate response with non-approved treatment options, and received a single d","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49393558/kyverna-stock-rockets-after-cell-therapy-helps-patients-walk-again-in-rare-disorder","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["DSI","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4006","LU0963586101.USD","LU2065731478.USD","BK4187","BK4588","BK4139","IE0031619046.USD","IE00B19Z4B17.USD","CRS","BK4585","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591964295","title":"Kyverna Therapeutics Shares Jump 39% After Co's Cell Therapy Meets Main Goal of Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591964295","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591964295?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:31","pubTimestamp":1765809092,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591774644","title":"BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNow","url":"https://stock-news.laohu8.com/highlight/detail?id=2591774644","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591774644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:18","pubTimestamp":1765808318,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNowEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","APD","FMC","AU","NEM","LU2931357623.SGD","ZTS","LU1778281490.HKD","KLAC","BK4564","LU0256863811.USD","CVNA","LYB","NVMI","LU0640476718.USD","CRBG","LU2237443382.USD","FAST","LU1223082196.USD","BK4551","SCCO","IE00BZ9MQY76.HKD","LU0265550946.USD","IE0034235303.USD","LU0158827948.USD","LU1989763005.USD","NCLH","IE00BJJMRY28.SGD","HL","KYTX","LU0011850046.USD","LU2360106780.USD","FCX","LU2290526834.HKD","DG","IE0009356076.USD","NOW","LU2125909916.SGD","BK4550","CDE","LU1153585028.USD","AMAT","MU","LU1551013342.USD","LRCX","MIST","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2591363641","title":"Kyverna Exec Says in Kysa-8 Trial, Median Age of 26 Patients Was 56 Years - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2591363641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591363641?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:22","pubTimestamp":1765804928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591720649","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Rocket Lab, Applied Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2591720649","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591720649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:16","pubTimestamp":1765804566,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Rocket Lab, Applied MaterialsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL0O0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCLH","LRCX","CDE","LU0354030438.USD","LU1223082519.USD","BK4516","KLAC","LU0630314457.HKD","LU2458330169.SGD","IE00BD6J9T35.USD","LU0208291251.USD","IE00BLSP4239.USD","LU0788108826.HKD","LU0314104364.USD","IE00B4JS1V06.HKD","RKLB","BK4519","BK4570","NVMI","AMAT","AU","LU1261432733.SGD","LU1430594728.SGD","DG","BK4533","IE00BWXC8680.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0238689110.USD","LU1883866441.USD","LU2756315318.SGD","KYTX","NOW","NEM","LU2236285917.USD","BK4581","LU0612318971.USD","SCCO","FCX","IE00BMPRXR70.SGD","FMC","LU2089985449.USD","FAST","LU1119994496.HKD","HL","BK4207","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2591364634","title":"Kyverna Says Trial of Treatment for Stiff Person Syndrome Showed 'Significant' Benefit in Primary, Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2591364634","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591364634?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:27","pubTimestamp":1765801664,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics  said Monday that a phase 2 trial of mivocabtagene autoleucel, or miv-cel, to treat stiff person syndrome demonstrated \"statistically significant\" benefits in the primary and all secondary efficacy endpoints.The trial's primary endpoint was the change from baseline in a timed 25-foot walk, while secondary endpoints include the change from baseline in indexes including the Distribution-of-stiffness Index and the Heightened Sensitivity Scale, the company said.A single dose of miv-cel demonstrated a \"robust\" improvement in mobility, with 81% of the 26 dosed patients exceeding a 20% improvement in the primary endpoint, Kyverna said. The product candidate was also well-tolerated, the company added.Kyverna said it plans to submit a biologics license application in H1 2026.Shares of Kyverna Therapeutics were up more than 15% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643667","title":"Kyverna Therapeutics Shares Surge 24% Premarket After Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643667?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:33","pubTimestamp":1765798399,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643665","title":"Kyverna's cell therapy meets main goal of mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643665?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:33","pubTimestamp":1765798381,"startTime":"0","endTime":"0","summary":"Kyverna's cell therapy meets main goal of mid-stage studyDec 15  - Kyverna Therapeutics KYTX.O said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643548","title":"Kyverna Therapeutics Inc - Miv-Cel Well-Tolerated With No High-Grade Crs or Icans","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643548?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA85CM7C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643506","title":"Kyverna Therapeutics Inc - Miv-Cel Achieves Significant Clinical Benefit After One Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643506?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA85CM7C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643392","title":"Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial of Miv-Cel (Kyv-101) in Stiff Person Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643392?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA85CM7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591064351","title":"Kyverna Therapeutics Inc - to Submit Bla to FDA for SPS in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591064351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591064351?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA85CM7C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591439736","title":"Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2591439736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591439736?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798200,"startTime":"0","endTime":"0","summary":"Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205250/0/en/Kyverna-Therapeutics-Announces-Positive-Topline-Data-from-Registrational-KYSA-8-Trial-of-Miv-cel-KYV-101-in-Stiff-Person-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","IE00B19Z4B17.USD","DSI","KYTX","BK4230","BK4585","LU0963586101.USD","IE00B7SZL793.SGD","BK4022","IE0031619046.USD","BK4139","CRS","BK4588","LU2065731478.USD","CAR","BK4187","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591643584","title":"Kyverna Therapeutics Shares Gain Ahead of Mid-Stage Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643584","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643584?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:28","pubTimestamp":1765798080,"startTime":"0","endTime":"0","summary":"Shares of Kyverna Therapeutics climbed after the company said it would disclose topline results from a mid-stage trial of its treatment for stiff person syndrome.The stock rose 20%, to $10.50, in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year.The Emeryville, Calif., biopharmaceutical company on Sunday said it would host a call to review results from its registrational phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome.Stiff person syndrome refers to a rare autoimmune neurological disorder that most commonly causes muscle stiffness and painful spasms that come and go and can worsen over time.The call is scheduled for 8 a.m. ET Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591664608","title":"Kyverna Therapeutics to Report Topline Phase 2 Results for KYV-101 in Stiff Person Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2591664608","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591664608?lang=en_us&edition=fundamental","pubTime":"2025-12-15 03:30","pubTimestamp":1765740611,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. announced that it will report topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in patients with stiff person syndrome . The results will be presented during a live webcast and conference call scheduled for December 15, 2025. Presentation materials and an archived replay will be available on the company's investor relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nNDLcgLFJM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","KYTX","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4585","BK4139","LU2210149790.SGD","SG9999014013.SGD","BK4112","LU2210150020.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}